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Pffectiveness of Sirolimus-Eluting Stent Implantation
or the Treatment of Ostial Left Anterior Descending
rtery Stenosis With Intravascular Ultrasound Guidance
i-Bae Seung, MD,* Young-Hak Kim, MD,† Duk-Woo Park, MD,† Bong-Ki Lee, MD,†
heol Whan Lee, MD,† Myeong-Ki Hong, MD,† Pum-Joon Kim, MD,* Wook-Sung Chung, MD,*
eung-Jea Tahk, MD,‡ Seong-Wook Park, MD,† Seung-Jung Park, MD†
eoul and Suwon, Korea
OBJECTIVES This study was designed to evaluate the clinical and angiographic outcomes of sirolimus-
eluting stent (SES) implantation for ostial left anterior descending (LAD) lesions compared
with bare-metal stent (BMS) implantation.
BACKGROUND The effectiveness of SES implantation for ostial LAD lesions is currently unknown.
METHODS Sirolimus-eluting stents were implanted in 68 consecutive patients with ostial LAD stenoses.
The control group was composed of 77 patients treated with BMS during the preceding two
years. In the SES group, for complete lesion coverage, stent positioning was intentionally
extended into the distal left main coronary artery (LMCA) in 23 patients (34%) with
intermediate LMCA narrowing.
RESULTS Compared with the BMS group, the SES group had more multivessel involvement, received
fewer debulking atherectomies, underwent more direct stenting, had a greater number of
stents, and had more segments stented. The procedural success rate was 100% in both groups.
The six-month angiographic restenosis rate was significantly lower in the SES group than in
the BMS group (5.1% vs. 32.3%, p  0.001). During the one-year follow-up period, neither
death nor myocardial infarction occurred in either group, but target lesion revascularization
was less frequent in the SES group than in the BMS group (0% vs. 17%, p  0.001). In the
SES group, there were no restenoses in cases with LMCA coverage, compared with three
restenoses (7.9%) in cases with precise stent positioning (p  NS).
CONCLUSIONS Sirolimus-eluting stent implantation in ostial LAD lesions achieved excellent results
regarding restenosis and clinical outcomes compared with BMS implantation. This finding
may be associated with reduced neointimal hyperplasia and complete lesion coverage. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009Coll Cardiol 2005;46:787–92) © 2005 by the American College of Cardiology Foundation
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blthough previous studies have reported favorable outcomes
f percutaneous intervention in ostial left anterior descend-
ng artery (LAD) stenosis, stenting at this lesion remains
hallenging because of the frequent involvement of the
istal left main coronary artery (LMCA) and the potential
or left circumflex artery (LCX) closure (1–3). Furthermore,
epeat intervention for in-stent restenosis is not easy to
erform because it is technically more complex than the
ndex procedure.
Striking results of early trials using sirolimus-eluting
tents (SES) have extended generalized use of SES for
omplex coronary lesions (4–7). Recently, the safety and
fficacy of SES implantation in aorto-ostial lesions was
eported (8). However, there have been no published data
egarding the results of SES implantation for ostial LAD
tenosis. The present study sought to evaluate the clinical
nd angiographic outcomes of SES implantation for ostial
AD lesions compared with bare-metal stent (BMS)
mplantation.
From the *Catholic University Hospital, Seoul, Korea; †Asan Medical Center,
niversity of Ulsan College of Medicine, Seoul, Korea; and ‡Ajou University
ospital, Suwon, Korea. This study was partly supported by the Cardiovascular
esearch Foundation, Seoul, Korea, and a grant of the Korea Health 21 R&D
roject, Ministry of Health and Welfare, Korea (0412-CR02-0704-0001).o
Manuscript received February 25, 2005; revised manuscript received April 1, 2005,
ccepted April 25, 2005.ETHODS
tudy population and design. From March 2003 to Jan-
ary 2004, SES were implanted in 68 consecutive patients
ith de novo ostial LAD lesions in three cardiac centers
SES group). A control group was composed of 77 patients
reated with BMS during the preceding two years (BMS
roup) who had been included in our previous randomized
tudy (9). This study showed that debulking atherectomy
efore stenting for ostial LAD stenosis did not decrease
ngiographic restenosis (9). Ostial stenosis was defined as a
arrowing located within 3 mm of the vessel origin on the
iew of least foreshortened angiographic projection. Pa-
ients had either angina or objective evidence of ischemia
nd lesions with a diameter stenosis 50% and a reference
essel diameter 2.5 mm. Although the BMS group
ncluded lesions with lengths 15 mm, lesion length in the
ES group was not restricted. The following criteria were
sed for exclusion: contraindication to antiplatelet agents,
cute myocardial infarction within 48 h, left ventricular
ysfunction (ejection fraction 40%), previous bypass sur-
ery, heavily calcified lesions, significant involvement
50% of diameter stenosis) of the LMCA or the LCX
stium, and chronic total occlusion. The institutional review
oard approved the study, and informed consents were
btained.
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Sirolimus-Eluting Stent for Ostial Stenosis September 6, 2005:787–92tenting procedures. In the BMS group, stent placement
or exact positioning was performed as previously described
1,9). In the SES group, two different strategies were
pplied to the stenting procedure according to the presence
f intermediate narrowing at the distal LMCA. In cases
ith intermediate narrowing at the distal LMCA, the distal
MCA was intentionally covered with SES to achieve
omplete lesion coverage (SES-I group), whereas in lesions
ith a normal LMCA, SES was implanted in a way similar
o the BMS group (SES-II group). Intermediate LMCA
arrowing necessitating complete coverage was predeter-
ined as a visually estimated diameter stenosis 30% by
ngiography or cross-sectional narrowing 40% by intra-
ascular ultrasound (IVUS). The IVUS examination was
trongly encouraged for accurate lesion assessment and
ptimal stenting in both groups.
During the intervention, patients received an 8,000 U
eparin bolus with a repeat bolus to keep the activated
lotting time 250 s. The use of glycoprotein IIb/IIIa
nhibitors was left to the operator’s discretion. After stent-
ng, all patients received aspirin (200 mg/day) indefinitely.
he SES group was treated with clopidogrel (75 mg/day)
or six months. In the BMS group, either clopidogrel or
iclopidine (250 mg twice a day) was administered for at
east one month.
ngiographic analysis. All coronary angiograms were for-
arded to the Asan Medical Center (Seoul, Korea) and
nalyzed by two experienced angiographers not involved in
he procedure. Using the guiding catheter for magnification
alibration and an on-line quantitative coronary angio-
raphic system (ANCOR V2.0, Siemens, Solna, Sweden),
inimal luminal diameter (MLD), percent diameter steno-
is, and reference vessel diameter were measured before and
fter the intervention and at follow-up from the single
atched view showing the smallest luminal diameter. The
cute gain was calculated as the difference between the
LD before and after procedure. The late loss was defined
s the difference between in MLD after procedure and at
ollow-up.
VUS imaging and analysis. All IVUS images were also
orwarded to the Asan Medical Center and analyzed by two
xperienced sonographers not involved in the procedure.
ntravascular ultrasound was performed after the adminis-
Abbreviations and Acronyms
BMS  bare-metal stent
CSA  cross-sectional area
EEM  external elastic membrane
IVUS  intravascular ultrasound
LAD  left anterior descending coronary artery
LCX  left circumflex coronary artery
LMCA  left main coronary artery
MLD  minimal luminal diameter
SES  sirolimus-eluting stentration of 0.2 mg intracoronary nitroglycerin via a motorized cransducer pullback system (0.5 mm/s) and a commercial
canner (SCIMED, Boston Scientific, Natick, Massachu-
etts) that consisted of a 30-MHz transducer within a 3.2-F
maging sheath. Quantitative IVUS analysis was performed
or 61 lesions (90%) in the SES group and 59 lesions (77%)
n the BMS group. Validation of cross-sectional area (CSA)
easurements of external elastic membrane (EEM), lumen,
laque, and media by IVUS has been previously described
10). The plaque burden (%) was measured as 100 (EEM
SA  lumen CSA)/EEM CSA. In the SES group,
uantitative IVUS measurements at the distal LMCA were
lso performed. The measurements were done with a
ommercially available program for computerized planim-
try (TapeMeasure, Indec System, Mountain View,
alifornia).
linical definitions and follow-up. Procedural success
as defined as a Thrombolysis In Myocardial Infarction
TIMI) flow grade 3 and 30% residual diameter stenosis
ithout major procedural or in-hospital complications such
s death, Q-wave myocardial infarction, or emergency
ypass surgery. Deaths that could not be classified were
onsidered cardiac related. Significant stent-jail of the LCX
stium was defined as stent coverage and 50% diameter
tenosis at the LCX ostium after the procedure. Angio-
raphic restenosis was defined as 50% diameter stenosis
ithin a stented segment.
All patients were clinically evaluated by office visits or
elephone interviews. Major adverse cardiac events, includ-
ng cardiac death, non-fatal myocardial infarction, and
arget lesion revascularization, were obtained during the
ollow-up period. Repeat coronary angiography was rou-
inely performed at six months after stenting, or earlier if
linically indicated by symptoms or documentation of myo-
ardial ischemia.
tatistical analysis. Data are expressed as mean  1 SD
or continuous variables and as frequency (%) for categorical
ariables. Differences between groups were assessed by the
tudent t test for continuous variables and the chi-square
est or Fisher exact test (if an expected frequency is 5) for
ategorical variables. A p value 0.05 was considered
tatistically significant. Statistical analysis was performed
sing commercially available software (SPSS 11 for Win-
ows, SPSS Inc., Chicago, Illinois).
ESULTS
aseline characteristics. The baseline clinical characteris-
ics were similar between the two groups, except that the
ES group had more multivessel involvement than the
MS group (Table 1). The baseline angiographic and IVUS
ata are shown in Table 2. Angiographically, the SES group
ad a smaller reference diameter and a longer lesion length
han the BMS group.
rocedural results and in-hospital outcomes. The proce-
ural success rate was 100% in both groups. Procedural
haracteristics are summarized in Table 3. The SES group,
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September 6, 2005:787–92 Sirolimus-Eluting Stent for Ostial Stenosisompared with the BMS group, underwent more direct
tenting and fewer debulking atherectomies and had more
tents implanted per lesion and more segments stented. In
ddition, IVUS guidance and additional high-pressure bal-
oons were used more frequently in the SES group than in
he BMS group. The post-intervention MLD and lumen
SA were significantly larger in the BMS group due to
reater acute gain than in the SES group (Table 2).
owever, post-procedural diameter stenosis was not differ-
nt between the two groups due to the small reference
iameter in the SES group. The SES group had a trend
oward fewer significant stent-jail compared to the BMS
Table 1. Baseline Clinical Characteristics
Patients
Age, yrs
Male gender
Cardiac risk factors
Hypertension
Diabetes mellitus
Hypercholesterolemia
Current smoking
Previous percutaneous coronary intervention*
Clinical manifestation*
Stable angina
Unstable angina
Myocardial infarction within 2 weeks
Multi-vessel coronary disease (2 vessels)
Left ventricular ejection fraction, %
*Analyzed by Fisher exact test. Values are given as numbers
BMS  bare-metal stent; SES  sirolimus-eluting stent
Table 2. Quantitative Angiographic and Intrav
Lesions
Angiographic variables
Distal reference vessel diameter, mm
Lesion length, mm
Minimal lumen diameter, mm
Baseline
Final
Follow-up
Diameter stenosis, %
Baseline
Final 
Follow-up 
Acute gain, mm
Late loss, mm
Restenosis*
Intravascular ultrasound variables
EEM CSA, mm2
Baseline 1
Final 1
Lumen CSA, mm2
Baseline
Final
Plaque burden, %
Baseline
Final*Analyzed by Fisher exact test. Values are given as numbers (%) o
CSA  cross-sectional area; EEM  external elastic membranroup, without statistical significance (p 0.067) (Table 3).
eri-procedural creatine kinase-MB elevation 3 times the
pper normal value developed in five SES patients (7.4%)
nd in four BMS patients (5.2%) (p  0.591). There were
o cases of death, Q-wave myocardial infarction, emergency
ypass surgery, or stent thrombosis during hospitalization in
ither group.
ollow-up angiographic and clinical outcomes. Six-
onth angiographic follow-up was performed on 59 SES
atients (86.8%) and 62 BMS patients (80.5%). There was
o significant difference in mean time to angiographic
ollow-up between the two groups (5.9 vs. 6.0 months, p 
SES BMS p Value
68 77
8.2  9.0 57.8  7.9 0.756
8 (70.6) 62 (80.5) 0.163
0 (44.1) 26 (33.8) 0.201
6 (23.5) 14 (18.2) 0.428
2 (17.6) 21 (27.3) 0.168
4 (35.3) 37 (48.1) 0.120
6 (8.8) 4 (5.2) 0.389
0.145
3 (33.8) 15 (19.5)
1 (60.3) 56 (72.7)
4 (5.9) 6 (7.8)
3 (48.5) 7 (9.1) 0.001
1.3  8.7 62.9  9.9 0.318
r mean  SD.
ar Ultrasound Characteristics
S BMS p value
8 77
0.51 3.61  0.54 0.001
17.1 15.4  5.2 0.001
0.53 1.04  0.48 0.143
0.39 3.71  0.56 0.001
0.56 2.13  0.91 0.001
15.7 71.1  12.4 0.014
12.0 3.8  13.8 0.147
19.0 40.9  25.6 0.001
0.62 2.67  0.65 0.001
0.52 1.60  0.81 0.001
(5.1) 20/62 (32.3) 0.001
3.98 14.33  3.80 0.573
3.05 18.32  3.49 0.001
0.68 1.91  0.34 0.001
1.40 9.57  2.04 0.001
5.0 86.0  3.4 0.001
6.0 47.5  6.7 0.0015
4
3
1
1
2
2
4
3
6ascul
SE
6
2.86 
24.6 
0.92 
2.97 
2.77 
65.2 
6.9 
2.1 
1.90 
0.22 
3/59
3.91 
5.89 
2.35 
7.39 
82.3 
53.0 r mean  SD.
e; other abbreviations as in Table 1.
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Sirolimus-Eluting Stent for Ostial Stenosis September 6, 2005:787–92.76). Late lumen loss (0.22  0.52 mm vs. 1.60  0.81
m, p  0.001) and binary restenosis rate (5.1% vs. 32.3%,
 0.001) was significantly lower in the SES group than in
he BMS group (Table 2). Cumulative frequency curves of
he MLD before and after the procedure and at follow-up
re shown in Figure 1. Clinical follow-up at one year was
vailable for all patients in the two groups. At one year,
here were no deaths or Q-wave myocardial infarction in
ither group, but target lesion revascularization was signif-
cantly lower in the SES group than in the BMS group (0%
s. 16.9%, p  0.001). Three restenotic lesions occurred in
he SES group, all of which were focally involved and did
ot require repeat revascularization because they had angio-
raphic diameter stenosis 70% without symptoms or
bjective evidence of ischemia.
esults of two SES implantation techniques. Compari-
on of the quantitative angiographic and IVUS data be-
Table 3. Procedural Characteristics
Patients
Intervention of other coronary lesions
Direct stenting*
Debulking coronary atherectomy*
Cutting balloon angioplasty*
Guidance of intravascular ultrasound*
Use of glycoprotein IIb/IIIa inhibitors*
Use of additional high-pressure balloons
Stents per lesion
Contiguous stent length, mm
Maximal device size, mm
Maximal inflation pressure, atm
Kissing balloon inflation after stenting*
Stent-jail*
*Analyzed by Fisher exact test. Values are given as numbers
Abbreviations as in Table 1.igure 1. Comparison of the cumulative distribution curves for minimal lumina
are-metal stents before and immediately after the intervention and at six monween the SES-I group and the SES-II group is summa-
ized in Tables 4 and 5. The SES-I group had smaller MLD
nd more plaque burden at the distal LMCA than the
ES-II group. There were no statistically significant differ-
nces regarding target lesion characteristics. The reference
iameter and MLD of the LCX ostium in the SES-I group
as significantly smaller than that in the SES-II group, but
he diameter stenosis was not different between two groups
t baseline. Final kissing balloon dilation was more fre-
uently used in the SES-I group (39.1%) than in the SES-II
roup (6.7%) (p  0.001). Immediately after intervention,
here were no significant differences in quantitative angio-
raphic and IVUS results concerning target lesions between
he two groups, and this trend continued in the follow-up
ngiography. Additionally, the LCX ostial diameters after
tenting and at follow-up did not differ significantly be-
ween the two groups.
ES BMS p Value
8 77
27.9) 7 (9.1) 0.003
35.3) 0 (0) 0.001
1.5) 38 (49.4) 0.001
2.9) 0 (0) 0.218
89.7) 59 (76.6) 0.037
1.5) 2 (2.6) 1.000
57.4) 11 (14.7) 0.001
 0.6 1.0  0.2 0.001
 19.3 16.6  5.2 0.001
 0.39 3.94  0.56 0.037
 3.1 14.9  2.6 0.001
17.6) 4 (5.2) 0.031
1.5) 7 (9.1) 0.067
r mean  SD.S
6
19 (
24 (
1 (
2 (
61 (
1 (
39 (
1.4
31.2
3.77
17.6
12 (
1 (l diameter between the patients who received sirolimus-eluting stents and
ths’ follow-up.
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September 6, 2005:787–92 Sirolimus-Eluting Stent for Ostial StenosisISCUSSION
he major finding of this study is that SES implantation for
stial LAD lesions was safe without procedural complica-
ions or stent thrombosis and effective in decreasing in-stent
estenosis and target lesion revascularization as compared to
MS implantation. In addition, in cases with intermediate
Table 4. Comparisons of Quantitative Angiogr
S
Patients
Distal left main before procedure
Reference, mm 3.78 
Minimal lumen diameter, mm 2.38 
Diameter stenosis, % 33.8 
Left circumflex ostium
Reference diameter, mm 2.63 
Minimal lumen diameter, mm
Baseline 2.17 
Final 2.08 
Follow-up 1.99 
Diameter stenosis, %
Baseline 16.4 
Final 21.7 
Follow-up 24.1 
Stent-jail after procedure* 1
Target lesion
Lesion length, mm 21.7 
Distal reference diameter, mm 2.87 
Minimal lumen diameter, mm
Baseline 1.00 
Final 2.97 
Follow-up 2.88 
Diameter stenosis, %
Baseline 64.8 
Final 5.6 
Follow-up 6.2 
Restenosis* 0/2
*Analyzed by Fisher exact test. Values are given as numbers
SES-I  covering distal main coronary artery; SES-II 
able 5. Comparisons of Quantitative Intravascular Ultrasound
nalysis
SES-I SES-II p Value
atients 20 41
istal left main
Before procedure
EEM CSA, mm2 19.64  6.33 20.57  5.38 0.574
Lumen CSA, mm2 9.86  2.83 12.39  3.71 0.014
Plaque burden, % 48.01  11.47 39.75  8.22 0.004
arget lesion
Before procedure
EEM CSA, mm2 13.68  4.34 14.03  3.85 0.770
Lumen CSA, mm2 2.26  0.50 2.39  0.76 0.532
Plaque burden, % 82.28  5.06 82.30  5.06 0.993
After procedure
EEM CSA, mm2 15.41  3.11 16.11  3.03 0.420
Lumen CSA, mm2 7.35  1.69 7.42  1.25 0.866
Plaque burden, % 52.16  6.37 53.44  5.84 0.451
alues are given as mean  SD.c
CSA  cross-sectional area; EEM  external elastic membrane; SES-I 
overing distal main coronary artery; SES-II  precise location.istal LMCA involvement, stenting covering the distal
MCA across the LCX ostium with IVUS guidance achieved
omplete lesion coverage and led to favorable clinical outcomes
hat were comparable with precise location.
This study has been designed so that the results of SES
mplantation were compared with those of BMS implanta-
ion that was conducted during a different period. There-
ore, there are significant differences between the two
roups in terms of the clinical and procedural characteris-
ics. The BMS group had shorter and larger vessels and
ore debulking atherectomy, assuring greater acute gain.
n the other hand, a less restrictive approach applied to the
ES group, which had more complex lesion characteristics
mplying a higher risk of suboptimal procedure and reste-
osis. Nevertheless, the SES group achieved similar post-
rocedural diameter stenosis and remarkably lower inci-
ence of angiographic restenosis compared with the BMS
roup. These findings indicate that SES appear effective in
btaining favorable procedural results and improving long-
erm outcomes, even in complex ostial lesions.
Importantly, in this study, we performed a stenting
trategy for complete lesion coverage in cases with interme-
iate distal LMCA narrowing. The previous report sug-
ested that the relatively high restenosis rate (14.7%) in
stial lesions might be associated with incomplete lesion
c Analysis
SES-II p Value
45
4.00  0.54 0.157
3.67  0.62 0.001
7.7  13.7 0.001
3.09  0.59 0.004
2.78  0.66 0.001
2.73  0.58 0.936
2.63  0.57 0.254
10.0  14.3 0.120
13.5  15.0 0.513
13.3  14.4 0.320
0 (0) 0.338
26.1  18.8 0.321
2.85  0.53 0.873
0.88  0.52 0.400
2.97  0.42 0.936
2.71  0.65 0.270
65.4  13.4 0.902
4 7.6  12.6 0.513
9 0.3  21.9 0.224
3/38 (7.9) 0.546
r mean  SD.
e location.aphi
ES-I
23
0.66
1.01
25.8
0.63
0.59
0.69
0.69
18.7
22.8
21.8
(4.3)
12.9
0.48
0.54
0.35
0.32
19.4
10.9
11.8
1 (0)overage due to the technical difficulties encountered in
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Sirolimus-Eluting Stent for Ostial Stenosis September 6, 2005:787–92tent positioning (7,11). More specifically, our study
howed that mean late loss was similar to the results of the
ES implantation in aorto-ostial lesions, but the binary
estenosis rate was approximately half of the previous value
8). These more favorable results, compared with recent
ata of SES implantation for ostial lesions (7,8,11), may be
xplained by the different stenting strategy. Also, complete
esion coverage with provisional kissing balloon dilation in
ases with normal LCX showed the feasibility of this
echnique in preserving the LCX ostial patency after pro-
edure and at follow-up. This favorable result was experi-
nced in our recent study on the efficacy of SES for
nprotected LMCA (12).
tudy limitations. Our study has several limitations, in-
luding the fact that it was conducted in a non-randomized
asis and included a small study population. Furthermore,
he study period for the SES group was not extended long
nough to compare long-term clinical outcomes with the
MS group. Therefore, our findings cannot be directly
xtrapolated to the entire population with ostial LAD
esions. However, our study indicates that SES implantation
ith a modified stenting technique may achieve excellent
utcomes in ostial LAD lesions, similar to the outcomes
een in relatively simple coronary lesions (4,5).
onclusions. Sirolimus-eluting stent implantation in os-
ial LAD lesions achieves excellent results regarding angio-
raphic restenosis and clinical outcomes compared with
MS implantation. These results may be explained by
educed neointimal hyperplasia and the complete lesion
overage strategy.
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